# Effect of Maraviroc (MCV) on the Immunological Recovery of HIV-1 Discordant Patients With CD4 Lymphocyte Counts Below 200 Cells/mm3

> **NCT01235013** · PHASE4 · UNKNOWN · sponsor: **Hospital Clinic of Barcelona** · enrollment: 60 (estimated)

## Conditions studied

- HIV-1 Infection

## Interventions

- **DRUG:** Maraviroc

## Key facts

- **NCT ID:** NCT01235013
- **Lead sponsor:** Hospital Clinic of Barcelona
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2010-11-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01235013

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01235013, "Effect of Maraviroc (MCV) on the Immunological Recovery of HIV-1 Discordant Patients With CD4 Lymphocyte Counts Below 200 Cells/mm3". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01235013. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*